Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis
Journal of Circulating Biomarkers · 2016
DOI: 10.1177/1849454416668791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, 2016. Verfasst von Alejandro Bustamante und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Circulating cell-free DNA (cfDNA) has been described as a prognostic marker for several diseases. Its prognostic value for short-term outcome in stroke patients treated with intravenous thrombolysis remains unexplored. cfDNA was measured on admission in 54 tissue plasminogen activator (tPA)-treated patients and 15 healthy controls using a real-time quantitative polymerase chain reaction assay. Neurological outcome was assessed at 48 h. Predictors of neurological improvement were evaluated by logistic regression analysis, and the additional predictive value of cfDNA over clinical variables was determined by integrated discrimination improvement (IDI). Stroke patients presented higher baseline cfDNA than healthy controls (408.5 (179-700.5) vs. 153.5 (66.9-700.5) kilogenome-equivalents/L, p = 0.123). A trend towards lower cfDNA levels was found in patients who neurologically improved at 48 h (269.5 (143.3-680) vs. 504 (345.9-792.3) kilogenome-equivalents/L, p = 0.130). In logistic regression analysis, recanalization at 1 h and cfDNA < 302.75 kilogenome-equivalents/L was independently associated with neurological improvement after adjustment by age, gender and baseline National Institutes of Health Stroke Scale score. The addition of cfDNA to the clinical predictive model improved its discrimination (IDI = 21.2% (9.2-33.3%), p = 0.009). These data suggest that cfDNA could be a surrogate marker for monitoring tPA efficacy by the prediction of short-term neurological outcome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain.
- Stroke Program, Institute of Biomedicine of Seville, Hospital Universitario Virgen del Rocio, Seville, Spain.
- Department of Clinical Biochemistry, Hospital Universitario Virgen del Rocio (IBiS/CSIC/SAS/University of Seville), Seville, Spain.
- Stroke Unit, Department of Neurology, Hospital Universitary Vall d'Hebron, Barcelona, Spain.
Zitieren
APA
Bustamante, A., Mancha, F., Macher, H. C., García-Berrocoso, T., Giralt, D., Ribó, M., Guerrero, J. M., & Montaner, J. (2016). Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. Journal of Circulating Biomarkers. https://doi.org/10.1177/1849454416668791
Vancouver
Bustamante A, Mancha F, Macher HC, García-Berrocoso T, Giralt D, Ribó M, et al. Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. Journal of Circulating Biomarkers. 2016. doi:10.1177/1849454416668791
BibTeX
@article{Bustamante2016,
author = {Bustamante, Alejandro and Mancha, Fernando and Macher, Hada C and García-Berrocoso, Teresa and Giralt, Dolors and Ribó, Marc and Guerrero, Juan M and Montaner, Joan},
title = {Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis},
journal = {Journal of Circulating Biomarkers},
year = {2016},
doi = {10.1177/1849454416668791}
}
EUVIMED